AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg followed by 200 mg bid
Number of subjects: 306
Study 15290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg bid
Number of subjects: 306
Study 15290743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 11387349 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex) alone
Number of subjects: 0
Study 11387349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 0
Study 11387349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex and Tamoxifen in combination (ZT)
Number of subjects: 0
Study 11387349 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0
Study 11387349 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 11387349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 0
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Corporeal Shock Wave Lithotripsy (ESWL) and ureteroscopy (experimental group)
Number of subjects: 96
Study 9232736 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given information, not allowed to choose)
Number of subjects: 96
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who perceived they received information (both groups)
Number of subjects: 96
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who perceived they did not participate in decision-making (both groups)
Number of subjects: 96
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower educational level who perceived they received information
Number of subjects: 96
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educated patients who perceived they participated in decision-making
Number of subjects: 96
Study 9232736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a passive coping style who perceived they received information or participated in decision-making
Number of subjects: 96
Study 8448748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, four times daily for 3 months)
Number of subjects: 9
Study 8448748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8448748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 9
Study 3761977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A eyedrops
Number of subjects: 12
Study 31721185 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 2886
Study 31721185 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 2886
Study 31721185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886
Study 31721185 — intervention group
Group type: COMPARATOR
Intervention: Galcanezumab and Placebo
Number of subjects: 2886
Study 29246361 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm and SGA births
Number of subjects: 31988
Study 29246361 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-AGA births
Number of subjects: 31988
Study 29246361 — intervention group
Group type: EXPERIMENTAL
Intervention: Term-SGA births
Number of subjects: 31988
Study 29246361 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW births
Number of subjects: 31988
Study 29246361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 31988
Study 27089519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir
Number of subjects: 0
Study 27089519 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil
Number of subjects: 0
Study 27089519 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study 24636474 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 23
Study 24636474 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (abstaining from peanut)
Number of subjects: 23
Study 22727499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and etoricoxib
Number of subjects: 120
Study 22727499 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and etoricoxib
Number of subjects: 120
Study 22727499 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib alone
Number of subjects: 120
Study 20093149 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD with comorbid MDD
Number of subjects: 39
Study 20093149 — intervention group
Group type: COMPARATOR
Intervention: GAD without comorbid MDD
Number of subjects: 39
Study 20093149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GAD with and without MDD)
Number of subjects: 39
Study 18256708 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item physical activity screening question
Number of subjects: 1171
Study 15755321 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners
Number of subjects: 78
Study 11834991 — intervention group
Group type: EXPERIMENTAL
Intervention: PerCutaneous Compression Plate (PCCP)
Number of subjects: 115
Study 11834991 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 115
Study 10408635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12 mg Zn++/day for one month)
Number of subjects: 67
Study 10408635 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART therapy
Number of subjects: 67
Study 10408635 — intervention group
Group type: COMPARATOR
Intervention: Zinc deficiency
Number of subjects: 67
Study 8772215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (low-molecular-weight heparin) administered subcutaneously at a fixed dose of 120 Anti-Xa IU/kg twice a day for 10 days.
Number of subjects: 60
Study 8772215 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin administered intravenously.
Number of subjects: 60
Study 1965113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal NPC 567 (bradykinin antagonist)
Number of subjects: 0
Study 1965113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6162471 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tryptophan (50 mg/kg) administered twice daily for 7 days
Number of subjects: 0
Study 6162471 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tryptophan (50 mg/kg) administered either acutely or chronically
Number of subjects: 0
Study 6321356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1-2 g b.i.d.)
Number of subjects: 60
Study 6321356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 g b.i.d.)
Number of subjects: 60
Study 6321356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g u.i.d.)
Number of subjects: 60
Study 31570105 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA)
Number of subjects: 13
Study 31570105 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) on circulating tumor DNA (ctDNA)
Number of subjects: 13
Study 31570105 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA) and circulating tumor DNA (ctDNA)
Number of subjects: 13
Study 29337584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 498
Study 29337584 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 498
Study 26708332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 82
Study 24643203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 h
Number of subjects: 514
Study 24643203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 24643203 — intervention group
Group type: COMPARATOR
Intervention: Rotigotine 8 mg/24 h vs Placebo
Number of subjects: 514
Study 22503581 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS(2) score of 3 to 6
Number of subjects: 541
Study 22503581 — intervention group
Group type: COMPARATOR
Intervention: CHADS(2) score of 0
Number of subjects: 541
Study 20811078 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (6 weeks, 3 times weekly)
Number of subjects: 48
Study 20811078 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 48
Study 17635939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (low‐fat dietary modification, weight loss, and physical activity intervention)
Number of subjects: 373
Study 17635939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 373
Study 17635939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 373
Study 17635939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) users in intervention group
Number of subjects: 373
Study 15716846 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 51
Study 15716846 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 51
Study 12087018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 0
Study 12087018 — intervention group
Group type: COMPARATOR
Intervention: IA-2 antibody positive, GAD antibody negative group
Number of subjects: 0
Study 10443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 29 degrees C
Number of subjects: 8
Study 10443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 31.5 degrees C
Number of subjects: 8
Study 10443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean skin temperature of 34 degrees C
Number of subjects: 8
Study 10443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 8
Study 8777188 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback from a woman
Number of subjects: 137
Study 8777188 — intervention group
Group type: COMPARATOR
Intervention: Neutral feedback from a woman
Number of subjects: 137
Study 8777188 — intervention group
Group type: COMPARATOR
Intervention: Positive feedback from a woman
Number of subjects: 137
Study 8777188 — intervention group
Group type: EXPERIMENTAL
Intervention: High anger and hypermasculinity measures
Number of subjects: 137
Study 2140735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the supine position
Number of subjects: 6
Study 2140735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the seated position
Number of subjects: 6
Study 2140735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion in both positions
Number of subjects: 6
Study 547544 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg 17 beta‐estradiol or 250 mg estriol
Number of subjects: 105
Study 547544 — intervention group
Group type: COMPARATOR
Intervention: gel only (control group)
Number of subjects: 105
Study 30007939 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast milk (BM) group (proportion of BM=100%, n=56)
Number of subjects: 133
Study 30007939 — intervention group
Group type: COMPARATOR
Intervention: Predominantly formula-fed infants (BM ≤50%, n=38)
Number of subjects: 133
Study 30007939 — intervention group
Group type: COMPARATOR
Intervention: Predominantly BM group (BM 51%-99%, n=39)
Number of subjects: 133
Study 30007939 — intervention group
Group type: COMPARATOR
Intervention: Predominantly formula-fed group
Number of subjects: 133
Study 29891406 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention to reduce sitting time, including classroom and outdoor environmental measures.
Number of subjects: 88
Study 29891406 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention to reduce sitting time.
Number of subjects: 88
Study 29891406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 88
Study 26874388 — intervention group
Group type: EXPERIMENTAL
Intervention: PA pressure-guided HF management plus standard of care
Number of subjects: 550
Study 26874388 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment (blind therapy group)
Number of subjects: 550
Study 23990195 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 328
Study 23990195 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 328
Study 23990195 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 328
Study 23990195 — intervention group
Group type: COMPARATOR
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 328
Study 22773769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (ERT) using Evorel patches
Number of subjects: 11
Study 22773769 — intervention group
Group type: COMPARATOR
Intervention: No patch (control period)
Number of subjects: 11
Study 20367730 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17470697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerability safety margin screening at 14 J
Number of subjects: 426
Study 17470697 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation safety margin screening at 14 J
Number of subjects: 426
Study 17470697 — intervention group
Group type: COMPARATOR
Intervention: First shock efficacy
Number of subjects: 426
Study 15093987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg od
Number of subjects: 79
Study 15093987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 11399783 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times daily for 7 days
Number of subjects: 12
Study 11399783 — intervention group
Group type: COMPARATOR
Intervention: Chitosan (890 mg) three times daily for 7 days
Number of subjects: 12
Study 11399783 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Orlistat vs Chitosan
Number of subjects: 12
Study 9257889 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐CY (4 g/m2 i.v.) plus GM‐CSF (8 microg/kg/day s.c.)
Number of subjects: 40
Study 9257889 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF (10 microg/kg/day s.c.) alone
Number of subjects: 40
Study 9257889 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐CY plus GM‐CSF
Number of subjects: 40
Study 9257889 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 40
Study 7901864 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 5 micrograms/kg
Number of subjects: 0
Study 7901864 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 10 micrograms/kg
Number of subjects: 0
Study 7901864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3651279 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 72
Study 3651279 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 72
Study 31420414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (840→420 mg every 3 weeks)
Number of subjects: 156
Study 31420414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 31420414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 156
Study 28804870 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIM
Number of subjects: 128
Study 28804870 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 128
Study 25795927 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for perfectionism
Number of subjects: 42
Study 25795927 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study 23820187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 44092
Study 23820187 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol or Atenolol
Number of subjects: 44092
Study 21875697 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal varicocelectomy after 2 ml intratunical space injection of methylene blue
Number of subjects: 80
Study 21875697 — intervention group
Group type: COMPARATOR
Intervention: No mapping technique during subinguinal varicocelectomy
Number of subjects: 80
Study 19701034 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling and root planing early in the second trimester)
Number of subjects: 1760
Study 19701034 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (periodontal care after delivery)
Number of subjects: 1760
Study 19701034 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 1760
Study 17043961 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportan (enteral nutrition specific for tumor patients)
Number of subjects: 66
Study 17043961 — intervention group
Group type: COMPARATOR
Intervention: Basic diet (control group)
Number of subjects: 66
Study 15209485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine myelomeningocele repair
Number of subjects: 0
Study 15209485 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 11422091 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg qd lanepitant
Number of subjects: 84
Study 11422091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8637697 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection at 37 degrees C (body temperature)
Number of subjects: 40
Study 1569226 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate‐SMFP dentifrice
Number of subjects: 120
Study 1569226 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate‐SMFP dentifrice
Number of subjects: 120
Study 1569226 — intervention group
Group type: COMPARATOR
Intervention: Control SMFP dentifrice (no potassium salt)
Number of subjects: 120
Study 6378437 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 25 mg tds
Number of subjects: 70
Study 6378437 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-SR, 650 mg daily
Number of subjects: 70
Study 6378437 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol, 1 g 8th hourly
Number of subjects: 70
Study 6378437 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 250 mg mane and 500 mg nocte
Number of subjects: 70
Study 6378437 — intervention group
Group type: COMPARATOR
Intervention: Sulindac, 200 mg bd
Number of subjects: 70
Study 30831333 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPLATZER Amulet device
Number of subjects: 1878
Study 30831333 — intervention group
Group type: COMPARATOR
Intervention: Boston Scientific WATCHMAN device
Number of subjects: 1878
Study 29522535 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle levels of perceived stress
Number of subjects: 523
Study 29522535 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of perceived stress
Number of subjects: 523
Study 29522535 — intervention group
Group type: COMPARATOR
Intervention: Lowest levels of perceived stress
Number of subjects: 523
Study 26070532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (bedtime)
Number of subjects: 57
Study 24722423 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinzhen oral liquid
Number of subjects: 399
Study 24722423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 23379201 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% (instilled twice-daily)
Number of subjects: 267
Study 23379201 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 267
Study 23379201 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% (instilled 4-times daily)
Number of subjects: 267
Study 20199178 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg three times a day (Group 1)
Number of subjects: 74
Study 20199178 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg and pentoxifylline 400 mg each three times per day (Group 2)
Number of subjects: 74
Study 18572088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protocol
Number of subjects: 49
Study 18572088 — intervention group
Group type: COMPARATOR
Intervention: Nondiet group
Number of subjects: 49
Study 16079371 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 209
Study 16079371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 11849194 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of 1 g paracetamol
Number of subjects: 12
Study 11849194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11849194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets of paracetamol
Number of subjects: 12
Study 10029055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralight wheelchair
Number of subjects: 74
Study 10029055 — intervention group
Group type: COMPARATOR
Intervention: Standard wheelchair
Number of subjects: 74
Study 7737532 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5)
Number of subjects: 67
Study 7737532 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 67
Study 7737532 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrotypic analysis of antibody response
Number of subjects: 67
Study 1413291 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive protocol for hypertension screening
Number of subjects: 1700
Study 4064468 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide and 80% oxygen
Number of subjects: 12
Study 4064468 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 12
Study 30950565 — intervention group
Group type: COMPARATOR
Intervention: GSK3008356 single doses (5 to 200 mg)
Number of subjects: 104
Study 30950565 — intervention group
Group type: COMPARATOR
Intervention: GSK3008356 repeat doses (1, 3, and 10 mg twice daily for 14 days)
Number of subjects: 104
Study 30950565 — intervention group
Group type: COMPARATOR
Intervention: GSK3008356 single doses
Number of subjects: 104
Study 30950565 — intervention group
Group type: COMPARATOR
Intervention: GSK3008356 repeat doses
Number of subjects: 104
Study 30950565 — intervention group
Group type: COMPARATOR
Intervention: GSK3008356
Number of subjects: 104